Entyvio Improves Quality of Life, Work Productivity of Ulcerative Colitis Patients, Phase 3 Study Shows

Entyvio Improves Quality of Life, Work Productivity of Ulcerative Colitis Patients, Phase 3 Study Shows
Treatment with Entyvio (vedolizumab), delivered into the blood or under the skin, led to significant clinical improvements and in quality of life, as well as work productivity in patients with moderate-to-severe ulcerative colitis, a Phase 3 clinical trial showed. The results were presented in a poster titled “Effects of subcutaneous vedolizumab on health-related quality of life and work productivity in patients with ulcerative colitis: results from the Phase 3 VISIBLE 1 trial,” at the 14thCongress of ECCO, March 6-9 in Copenhagen, Denmark. The quality of life of patients with UC is often impaired, and clinical trials testing investigational therapies for UC also should include the therapy’s effects on this important outcome. Researchers analyzed data from the Phase 3 VISIBLE 1 trial, evaluating Takeda Pharmaceutical’s new subcutaneous (under-the-skin) form of Entyvio to assess the therapy’s effects in the UC patient’s quality of life and work productivity. The VISIBLE 1 (NCT02611830) recruited adult patients with moderate-to-severe UC who already had achieved a meaningfu
Subscribe or to access all post and page content.